Aducanumab Approval Decision Delayed: Could This Be Good News?
Amendment Triggered Three-Month Review Extension
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.
You may also be interested in...
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.
Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.